Rapid emergence of daptomycin resistance in clinical isolates of Corynebacterium striatum… a cautionary tale

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 12, 2014, Pages 2199-2205

  McElvania TeKippe, E ^a   Thomas, B S ^a   Ewald, G A ^a   Lawrence, S J ^a   Burnham, C A D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; LINEZOLID; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSCESS DRAINAGE; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORYNEBACTERIUM INFECTION; CORYNEBACTERIUM STRIATUM; DEBRIDEMENT; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR ASSIST DEVICE; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PHENOTYPE; TRANSTHORACIC ECHOCARDIOGRAPHY; CORYNEBACTERIUM; CORYNEBACTERIUM INFECTIONS; DRUG EFFECTS; HEART ASSIST DEVICE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYOCARDIAL ISCHEMIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CORYNEBACTERIUM; CORYNEBACTERIUM INFECTIONS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HEART-ASSIST DEVICES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 84911980015     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2188-6     Document Type: Article

References (37)

1. Gould IM, Miró JM, Rybak MJ (2013) Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42(3):202–210. doi:10.1016/j.ijantimicag.2013.05.005
2. Humphries RM, Pollett S, Sakoulas G (2013) A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26(4):759–780. doi:10.1128/CMR.00030-13
3. Rybak JM, Barber KE, Rybak MJ (2013) Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother 14(14):1919–1932. doi:10.1517/14656566.2013.820276
4. Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, Pigrau Serrallach C, Guerra Farfán E, Amat Mateu C, Flores Sanchez X (2012) Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 67(7):1749–1754. doi:10.1093/jac/dks119
5. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, Agrusta F, Caprioli R, Albisinni R, Ragone E, Utili R (2012) High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54(3):347–354. doi:10.1093/cid/cir805
6. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) (2014) University of Alabama at Birmingham. Accessed 3 Feb 2014
7. Lee PP, Ferguson DA Jr, Sarubbi FA (2005) Corynebacterium striatum: an underappreciated community and nosocomial pathogen. J Infect 50(4):338–343. doi:10.1016/j.jinf.2004.05.005
8. Funke G, von Graevenitz A, Clarridge JE 3rd, Bernard KA (1997) Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 10(1):125–159
9. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT (2003) In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47(6):1968–1971
10. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT (2003) In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47(1):337–341
11. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5(11):e1000660. doi:10.1371/journal.ppat.1000660
12. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200(12):1916–1920. doi:10.1086/648473
13. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104(22):9451–9456. doi:10.1073/pnas.0609839104
14. Kaatz GW, Lundstrom TS, Seo SM (2006) Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 28(4):280–287. doi:10.1016/j.ijantimicag.2006.05.030
15. Friedman L, Alder JD, Silverman JA (2006) Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50(6):2137–2145. doi:10.1128/AAC.00039-06
16. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, François P, Peschel A, Bayer AS (2009) Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53(6):2636–2637. doi:10.1128/AAC.01415-08
17. Bayer AS, Schneider T, Sahl HG (2013) Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139–158. doi:10.1111/j.1749-6632.2012.06819.x
18. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365(10):892–900. doi:10.1056/NEJMoa1011138
19. Munita JM, Tran TT, Diaz L, Panesso D, Reyes J, Murray BE, Arias CA (2013) A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 57(6):2831–2833. doi:10.1128/AAC.00021-13
20. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS (2011) Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 55(7):3345–3356. doi:10.1128/AAC.00207-11
21. Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray BE, Arias CA (2012) Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 56(8):4354–4359. doi:10.1128/AAC.00509-12
22. Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S (2009) Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. J Clin Microbiol 47(7):2328–2331. doi:10.1128/JCM.00457-09
23. Tran TT, Jaijakul S, Lewis CT, Diaz L, Panesso D, Kaplan HB, Murray BE, Wanger A, Arias CA (2012) Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother 56(6):3461–3464. doi:10.1128/AAC.00046-12
24. McElvania Tekippe E, Shuey S, Winkler DW, Butler MA, Burnham CA (2013) Optimizing identification of clinically relevant Gram-positive organisms by use of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system. J Clin Microbiol 51(5):1421–1427. doi:10.1128/JCM.02680-12
25. Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez M, Burnham CA (2013) Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 57(1):559–568. doi:10.1128/AAC.01633-12
26. El Feghaly RE, Stamm JE, Fritz SA, Burnham CA (2012) Presence of the bla(Z) beta-lactamase gene in isolates of Staphylococcus aureus that appear penicillin susceptible by conventional phenotypic methods. Diagn Microbiol Infect Dis 74(4):388–393. doi:10.1016/j.diagmicrobio.2012.07.013
27. Clinical and Laboratory Standards Institute (CLSI) (2013) Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI document M100-S23. CLSI, Wayne, PA
28. Ghide S, Jiang Y, Hachem R, Chaftari AM, Raad I (2010) Catheter-related Corynebacterium bacteremia: should the catheter be removed and vancomycin administered? Eur J Clin Microbiol Infect Dis 29(2):153–156. doi:10.1007/s10096-009-0827-0
29. Fernández Guerrero ML, Molins A, Rey M, Romero J, Gadea I (2012) Multidrug-resistant Corynebacterium striatum endocarditis successfully treated with daptomycin. Int J Antimicrob Agents 40(4):373–374. doi:10.1016/j.ijantimicag.2012.06.001
30. Fernández Guerrero ML, Robles I, Nogales Mdel C, Nuevo D (2013) Corynebacterium striatum: an emerging nosocomial drug-resistant endocardial pathogen. J Heart Valve Dis 22(3):428–430
31. Sader HS, Flamm RK, Farrell DJ, Jones RN (2013) Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groups. Antimicrob Agents Chemother 57(12):6378–6380. doi:10.1128/AAC.01906-13
32. Fernandez-Roblas R, Adames H, Martín-de-Hijas NZ, Almeida DG, Gadea I, Esteban J (2009) In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus Corynebacterium. Int J Antimicrob Agents 33(5):453–455. doi:10.1016/j.ijantimicag.2008.11.001
33. van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis 30(5):603–610. doi:10.1007/s10096-010-1128-3
34. Montero CI, Stock F, Murray PR (2008) Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 52(3):1167–1170. doi:10.1128/AAC.00774-07
35. Bryant KA, Roberts AL, Rupp ME, Anderson JR, Lyden ER, Fey PD, Van Schooneveld TC (2013) Susceptibility of enterococci to daptomycin is dependent upon testing methodology. Diagn Microbiol Infect Dis 76(4):497–501. doi:10.1016/j.diagmicrobio.2013.04.019
36. Palavecino EL, Burnell JM (2013) False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci. J Clin Microbiol 51(1):281–283. doi:10.1128/JCM.01721-12
37. Nakashima H, Takahashi H, Kameko M, Saito H (2012) Daptomycin Etest MICs for methicillin-resistant Staphylococcus aureus vary among different media. J Infect Chemother 18(6):970–972. doi:10.1007/s10156-012-0424-5